Better Response, Survival in Head and Neck Cancer With Dual Pre-Op Immunotherapy

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single drug, a small randomized trial showed.

The pathologic tumor response (pTR) rate increased from 41.6% with single-agent nivolumab (Opdivo) to 63.6% with nivolumab plus the CTLA-4 inhibitor ipilimumab (Yervoy) and 73.3% with nivolumab plus the LAG3 inhibitor relatlimab (Opdualag). The combinations led to more major pathologic responses, which were associated with better disease free and overall survival at 3 years.

https://www.medpagetoday.com/hematologyoncology/othercancers/114724